Bioventus Inc. (BVS)
Makes injectable treatments and surgical devices to relieve joint pain and repair bone
$13.21+0.06%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+113.8%
The outlook
BVS is trading near its 52-week high and sits above both its 50- and 200-day moving averages, signaling upward momentum. Analysts rate the stock bullishly, with an average price target about 12% above the current level. The trailing P/E of 32.2 suggests the stock commands a premium valuation relative to current earnings.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range100% of the way from its 52-week low to high
Price targetAvg target +12% vs current price
Analyst price target
~12-month · 5 analysts$14.80average target+12.0% vs now
Now $13.21
Low $14.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$895.0M
52-wk high
$13.21
52-wk low
$5.81
50-day avg
$10.12
200-day avg
$8.70
Trailing P/E
32.2